Mylan launches review to unlock firm’s“true value”
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Mylan has put together a board committee which is “actively evaluating a wide range of alternatives to unlock the true value of our one-of-a-kind platform”. Describing current “negative trends and dynamics” in the US as “unsustainable for the US healthcare system”, Mylan insisted investors “under-appreciate and under-value the durability, differentiation and strengths of Mylan’s global diversified business”.
You may also be interested in...
Aspen And Mylan Strike A Deal On Australia And New Zealand Portfolio
Mylan has bolstered its presence in key Australasian markets through a portfolio distribution arrangement with Aspen Pharma, which includes an option to buy in March 2019; the South African firm, on the other hand, is continuing to manage its portfolio in the markets, “allowing enhanced operational focus and removing complexity.”
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.